-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company’s pipeline in vascular anomalies -- Announced nomination of OKI-345, a next generation PI3Kα pan-mutant
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3K α pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations -- Next-generation PI3K α pan-mutant inhibitor development candidate for HR+ metastatic breast cancer is expected to be announced in March 2026 --
